3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Polycystic Ovary Syndrome
7
Neoplasms
6
Breast Neoplasms
6
Vomiting
2
Solid Tumors
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Diabetes Mellitus
2
Weight Gain
1
Venous Thromboembolism
1
Uterine Cervical Neoplasms
1
Uterine Cervical Dysplasia
1
Urinary Bladder Neoplasms
1
Thrombocythemia, Essential
1
Stem Cell Transplant Complications
1
Skin Toxicity
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Premature Birth
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pre-Eclampsia
1
Polycythemia Vera
1
Parathyroid Neoplasms
1
Pain, Postoperative
1
Ovarian Neoplasms
1
Nausea
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Interventions
fludarabine phosphate
58
Cyclophosphamide
54
Peripheral Blood Stem Cell Transplantation
49
Mycophenolic Acid
39
Busulfan
38
Tacrolimus
37
Cyclosporine
33
Antilymphocyte Serum
33
Whole-Body Irradiation
32
Filgrastim
28
Methotrexate
27
Radiotherapy
20
Melphalan
18
Cytarabine
17
fludarabine
16
Etoposide
16
Methylprednisolone
14
ruxolitinib
11
sargramostim
9
Flow Cytometry
9
Cyclosporins
9
Cord Blood Stem Cell Transplantation
9
Alemtuzumab
9
thymoglobulin
8
Sirolimus
8
Psychiatric Rehabilitation
8
Granulocyte Colony-Stimulating Factor
8
Azacitidine
8
merphos
7
Decitabine
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Myeloproliferative Disorders
×
Tablets
×
Clear all
NCT04243122
2024-05-29
AIRPORT-MPN
Ottawa Hospital Research Institute
Phase 2
Completed
44 enrolled